EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma

Ugur Sener iD, Mason Webb iD, William G Breen, Bryan J Neth, Nadia N Laack, David Routman, Paul D Brown, Anita Mahajan, Kelsey Frechette, Arkadiusz Z Dudek, Svetomir N Markovic, Matthew S Block und 6 weitere

Journal of Immunotherapy and Precision Oncology · 01.02.2024 · 7 (1) · 1-6

DOI: 10.36401/jipo-23-20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 05.02.2024. Verfasst von Ugur Sener und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, MN, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Proton craniospinal irradiation (pCSI) is a treatment option for leptomeningeal disease (LMD), which permits whole neuroaxis treatment while minimizing toxicity. Despite this, patients inevitably experience progression. Adding systemic therapy to pCSI may improve outcomes.

Methods

In this single-institution retrospective case series, we present the feasibility of treatment with pCSI (30Gy, 10 fractions) and an immune checkpoint inhibitor (ICI) in two sequential patients with LMD from melanoma.

Results

The first patient developed LMD related to BRAF V600E-mutant melanoma after prior ICI and BRAF-targeted therapy. After pCSI with concurrent nivolumab, the addition of relatlimab, and BRAF-targeted therapy, he remained alive 7 months after LMD diagnosis despite central nervous system progression. The second patient developed LMD related to BRAF-wildtype melanoma after up-front ICI. He received pCSI with concurrent ipilimumab and nivolumab, then nivolumab maintenance. Though therapy was held for ICI hepatitis, the patient remained progression-free 5 months after LMD diagnosis.

Conclusion

Adding an ICI to pCSI is feasible for patients with LMD and demonstrates a tolerable toxicity profile. While prospective evaluation is ultimately warranted, pCSI with ICI may confer survival benefits, even after prior ICI.

Schlagwörter

Stichwörter der Autor:innen

craniospinal irradiationimmune checkpoint inhibitorsimmunotherapyleptomeningeal diseaseproton therapy

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Ugur Sener, Mason Webb

Förderung

  • NCATS NIH HHS

Zitieren

APA

Sener, U., Webb, M., Breen, W. G., Neth, B. J., Laack, N. N., Routman, D., Brown, P. D., Mahajan, A., Frechette, K., Dudek, A. Z., Markovic, S. N., Block, M. S., McWilliams, R. R., Dimou, A., Kottschade, L. A., Montane, H. N., Kizilbash, S. H., & Campian, J. L. (2024). Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. Journal of Immunotherapy and Precision Oncology, 7(1), 1-6. https://doi.org/10.36401/jipo-23-20

Vancouver

Sener U, Webb M, Breen WG, Neth BJ, Laack NN, Routman D, et al. Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma. Journal of Immunotherapy and Precision Oncology. 2024;7(1):1-6. doi:10.36401/jipo-23-20

BibTeX
@article{Sener2024,
  author = {Sener, Ugur and Webb, Mason and Breen, William G and Neth, Bryan J and Laack, Nadia N and Routman, David and Brown, Paul D and Mahajan, Anita and Frechette, Kelsey and Dudek, Arkadiusz Z and Markovic, Svetomir N and Block, Matthew S and McWilliams, Robert R and Dimou, Anastasios and Kottschade, Lisa A and Montane, Heather N and Kizilbash, Sani H and Campian, Jian L},
  title = {Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2024},
  volume = {7},
  number = {1},
  pages = {1--6},
  doi = {10.36401/jipo-23-20}
}
Kostenlos starten →